These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20382086)

  • 41. New drugs and regimens for treatment of TB.
    Leibert E; Rom WN
    Expert Rev Anti Infect Ther; 2010 Jul; 8(7):801-13. PubMed ID: 20586565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.
    Biava M; Porretta GC; Poce G; Battilocchio C; Alfonso S; de Logu A; Manetti F; Botta M
    ChemMedChem; 2011 Apr; 6(4):593-9. PubMed ID: 21341373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tuberculosis: the drug development pipeline at a glance.
    Villemagne B; Crauste C; Flipo M; Baulard AR; Déprez B; Willand N
    Eur J Med Chem; 2012 May; 51():1-16. PubMed ID: 22421275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Models and approaches for anti-TB drug testing.
    Yasinskaya Y; Sacks L
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):823-31. PubMed ID: 21810054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new TB drug by 2010--or sooner?
    Crabb C
    Bull World Health Organ; 2002; 80(6):518-9. PubMed ID: 12132015
    [No Abstract]   [Full Text] [Related]  

  • 47. Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches.
    Tandon R; Nath M
    Mini Rev Med Chem; 2017; 17(6):549-570. PubMed ID: 27280980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pipeline of drugs for related diseases: tuberculosis.
    Dooley KE; Nuermberger EL; Diacon AH
    Curr Opin HIV AIDS; 2013 Nov; 8(6):579-85. PubMed ID: 24100880
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhaled drug therapy for treatment of tuberculosis.
    Misra A; Hickey AJ; Rossi C; Borchard G; Terada H; Makino K; Fourie PB; Colombo P
    Tuberculosis (Edinb); 2011 Jan; 91(1):71-81. PubMed ID: 20875771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives.
    Jadhavar PS; Vaja MD; Dhameliya TM; Chakraborti AK
    Curr Med Chem; 2015; 22(38):4379-97. PubMed ID: 26549430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel agents in the management of Mycobacterium tuberculosis disease.
    Barry PJ; O'Connor TM
    Curr Med Chem; 2007; 14(18):2000-8. PubMed ID: 17691942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
    van den Boogaard J; Kibiki GS; Kisanga ER; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2009 Mar; 53(3):849-62. PubMed ID: 19075046
    [No Abstract]   [Full Text] [Related]  

  • 53. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity.
    Davies GR
    Tuberculosis (Edinb); 2010 May; 90(3):171-6. PubMed ID: 20382567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New trends in development of antimycobacterial compounds.
    Biava M; Porretta GC; Deidda D; Pompei R
    Infect Disord Drug Targets; 2006 Jun; 6(2):159-72. PubMed ID: 16789877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.
    Sarathy J; Dartois V; Dick T; Gengenbacher M
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1648-53. PubMed ID: 23335744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug resistance in Mycobacterium tuberculosis and targeting the l,d-transpeptidase enzyme.
    Gokulan K; Varughese KI
    Drug Dev Res; 2019 Feb; 80(1):11-18. PubMed ID: 30312987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The magic bullets and tuberculosis drug targets.
    Zhang Y
    Annu Rev Pharmacol Toxicol; 2005; 45():529-64. PubMed ID: 15822188
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The TB Alliance: overcoming challenges to chart the future course of TB drug development.
    Ginsberg A
    Future Med Chem; 2011 Aug; 3(10):1247-52. PubMed ID: 21859299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A potentially new treatment for tuberculosis; will a diarylquinoline work for leprosy?
    Franzblau S
    Int J Lepr Other Mycobact Dis; 2005 Mar; 73(1):32. PubMed ID: 15898838
    [No Abstract]   [Full Text] [Related]  

  • 60. Tuberculosis drugs: new candidates and how to find more.
    Sala C; Hartkoorn RC
    Future Microbiol; 2011 Jun; 6(6):617-33. PubMed ID: 21707310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.